| Print
89bio (ETNB)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Address
Forecast key dates
Name | Key Date |
---|---|
89bio Inc Annual General Meeting for 2025 | 2025-05-29T09:00:00 |
89bio Inc First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
89bio Inc Fourth Quarter Earnings Results for 2024 | 2025-02-28T00:00:00 |
89bio Inc Annual Report for 2024 | 2025-02-28T00:00:00 |
89bio Inc Third Quarter Earnings Results for 2024 | 2024-11-08T00:00:00 |
89bio Inc Second Quarter Earnings Results for 2024 | 2024-08-09T00:00:00 |
89bio Inc Annual General Meeting for 2024 | 2024-05-29T09:00:00 |
89bio, Inc. KOL Webinar on the Pegozafermin Opportunity 2024 | 2024-05-16T10:00:00 |
89bio Inc to Present at BofA Securites 2024 Health Care Conference | 2024-05-15T14:20:00 |
89bio Inc First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
89bio Inc Annual General Meeting for 2024 | 2024-05-29T09:00:00 |
89bio, Inc. KOL Webinar on the Pegozafermin Opportunity 2024 | 2024-05-16T10:00:00 |
89bio Inc to Present at BofA Securites 2024 Health Care Conference | 2024-05-15T14:20:00 |
89bio Inc First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
89bio to Participate in the Leerink Partners Global Biopharma Conference | 2024-03-12T13:40:00 |
89bio Inc Annual Report for 2023 | 2024-03-01T00:00:00 |
89bio Inc Fourth Quarter Earnings Results for 2023 | 2024-02-29T00:00:00 |
89bio Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2024-02-13T13:20:00 |
89bio Inc Third Quarter Earnings Results for 2023 | 2023-11-08T00:00:00 |
89bio Inc Second Quarter Earnings Results for 2023 | 2023-08-09T00:00:00 |
89bio Inc Annual General Meeting for 2023 | 2023-06-05T09:00:00 |
89bio Inc First Quarter Earnings Results for 2023 | 2023-05-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.